GlassScriptPhysician profile
Montish Singla
NPI 1083921183
$5,106.67
in general payments reported to CMS, 2019-2025
29 companies · $981 in 2025
The $981 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $149 · 2021: $599 · 2022: $940 · 2023: $1,043 · 2024: $1,060 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,032 · Education: $52.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,031.75 |
| Education | $52.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $626.84 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $584.93 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $433.46 | 2022-2025 | |
| Horizon Therapeutics Plc | $390.52 | 2019-2023 | Krystexxa |
| Amgen INC. | $366.01 | 2021-2025 | Tavneos, Parsabiv, Krystexxa |
| Travere Therapeutics, INC. | $361.28 | 2020-2025 | |
| Vifor Pharma, INC. | $288.19 | 2019-2025 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $278.12 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $206.60 | 2019-2025 | Injectafer |
| Fresenius USA Marketing, INC. | $165.56 | 2019-2024 | Velphoro, Korsuva |
| Novartis Pharmaceuticals Corporation | $147.39 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $138.48 | 2020-2023 | Acthar |
| Glaxosmithkline, LLC. | $135.40 | 2022-2024 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $128.75 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $113.26 | 2022-2024 | Lupkynis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $109.54 | 2022 | |
| Akebia Therapeutics INC | $87.87 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $82.14 | 2019-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.21 | 2023-2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $63.62 | 2025 | Empaveli |
| Lilly USA, LLC | $63.22 | 2023-2024 | Jardiance |
| Genzyme Corporation | $52.30 | 2019-2024 | |
| Scpharmaceuticals INC. | $46.56 | 2024-2025 | |
| Ardelyx, INC. | $40.22 | 2023-2024 | Ibsrela |
| Mallinckrodt Enterprises LLC | $38.66 | 2019 | |
| Lemaitre Vascular, INC. | $31.10 | 2024 | Artegraft Vascular Graft |
| Amicus Therapeutics, INC. | $18.72 | 2022 | |
| Shire North American Group INC | $17.16 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Montish Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.